dragon pharma retatrutide 10mg by Official Retatrutide - Transforma Peptides

So we think there will be still some struggle for a couple of years

During the median follow-up of 15.9 months, 137 major adverse cardiovascular events (MACEs) (61/1591 patients (3.8%) in the oral semaglutide group and 76/1592 patients (4.8%) in the placebo group) were documented [52]

The 12 mg dose in TRIUMPH-4 led to a 28.7% loss over 68 weeks, while tirzepatide in the SURMOUNT-1 trial produced approximately 22.5% loss over 72 weeks

doi: 10.1111/dom.14476 [DOI] [PubMed] [Google Scholar] 4

The study focused on 9,848 GLP-1 prescriptions ordered between January 2018 and September 2022 for 6,094 patients who were enrolled either in Medicare or commercial insurance